Skip to content

Trial Summary

The primary objectives of the study are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of SG in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin) in participants with advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations.



ACTRN/NCT /ethics:


Scientific title:

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Sponsor / Cooperative group:

Gilead Sciences

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2022-02-01
Anticipated End Date2026-02-01

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorDr Gonzalo Tapia Rico
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting